Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ONTY's Cash to Debt is ranked higher than
88% of the 1484 Companies
in the Global Biotechnology industry.

( Industry Median: 48.31 vs. ONTY: No Debt )
ONTY' s 10-Year Cash to Debt Range
Min: 5.92   Max: No Debt
Current: No Debt

Interest Coverage No Debt
ONTY's Interest Coverage is ranked higher than
78% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ONTY: No Debt )
ONTY' s 10-Year Interest Coverage Range
Min: 1060.29   Max: 9999.99
Current: No Debt

1060.29
9999.99
F-Score: 2
Z-Score: 7.90
M-Score: -1.71
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -55.38
ONTY's ROE (%) is ranked higher than
64% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: -28.35 vs. ONTY: -55.38 )
ONTY' s 10-Year ROE (%) Range
Min: -163.15   Max: 45.34
Current: -55.38

-163.15
45.34
ROA (%) -49.78
ONTY's ROA (%) is ranked higher than
62% of the 1489 Companies
in the Global Biotechnology industry.

( Industry Median: -22.44 vs. ONTY: -49.78 )
ONTY' s 10-Year ROA (%) Range
Min: -133.9   Max: 24.26
Current: -49.78

-133.9
24.26
ROC (Joel Greenblatt) (%) -3006.16
ONTY's ROC (Joel Greenblatt) (%) is ranked higher than
59% of the 1448 Companies
in the Global Biotechnology industry.

( Industry Median: -352.58 vs. ONTY: -3006.16 )
ONTY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -8811.02   Max: 661.2
Current: -3006.16

-8811.02
661.2
EBITDA Growth (3Y)(%) -16.30
ONTY's EBITDA Growth (3Y)(%) is ranked higher than
67% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. ONTY: -16.30 )
ONTY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -60   Max: 29.6
Current: -16.3

-60
29.6
EPS Growth (3Y)(%) -17.00
ONTY's EPS Growth (3Y)(%) is ranked higher than
68% of the 819 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. ONTY: -17.00 )
ONTY' s 10-Year EPS Growth (3Y)(%) Range
Min: -60.4   Max: 28.7
Current: -17

-60.4
28.7
» ONTY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ONTY Guru Trades in Q2 2014

Paul Tudor Jones 31,457 sh (+2.28%)
Murray Stahl 32,333 sh (unchged)
George Soros Sold Out
First Eagle Investment 2,384,039 sh (-12.51%)
» More
Q3 2014

ONTY Guru Trades in Q3 2014

Steven Cohen 721,075 sh (New)
Murray Stahl 32,333 sh (unchged)
First Eagle Investment Sold Out
Paul Tudor Jones 22,957 sh (-27.02%)
» More
Q4 2014

ONTY Guru Trades in Q4 2014

Paul Tudor Jones 22,957 sh (unchged)
Steven Cohen 721,075 sh (unchged)
Murray Stahl 32,333 sh (unchged)
» More
Q1 2015

ONTY Guru Trades in Q1 2015

Jim Simons 614,178 sh (New)
First Eagle Investment 1,300,000 sh (New)
Murray Stahl 33,333 sh (+3.09%)
Paul Tudor Jones 22,957 sh (unchged)
Steven Cohen 625,000 sh (-13.32%)
» More
» Details

Insider Trades

Latest Guru Trades with ONTY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 2.40
ONTY's P/B is ranked higher than
90% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. ONTY: 2.40 )
ONTY' s 10-Year P/B Range
Min: 0.75   Max: 23.93
Current: 2.4

0.75
23.93
EV-to-EBIT -3.69
ONTY's EV-to-EBIT is ranked higher than
70% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ONTY: -3.69 )
ONTY' s 10-Year EV-to-EBIT Range
Min: -170.5   Max: 10.1
Current: -3.69

-170.5
10.1
Current Ratio 20.64
ONTY's Current Ratio is ranked higher than
95% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. ONTY: 20.64 )
ONTY' s 10-Year Current Ratio Range
Min: 1.67   Max: 36.71
Current: 20.64

1.67
36.71
Quick Ratio 20.64
ONTY's Quick Ratio is ranked higher than
95% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. ONTY: 20.64 )
ONTY' s 10-Year Quick Ratio Range
Min: 0.95   Max: 36.71
Current: 20.64

0.95
36.71

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.00
ONTY's Price/Net Cash is ranked higher than
92% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 220.30 vs. ONTY: 4.00 )
ONTY' s 10-Year Price/Net Cash Range
Min: 1.03   Max: 38.63
Current: 4

1.03
38.63
Price/Net Current Asset Value 4.00
ONTY's Price/Net Current Asset Value is ranked higher than
91% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 46.00 vs. ONTY: 4.00 )
ONTY' s 10-Year Price/Net Current Asset Value Range
Min: 0.9   Max: 38
Current: 4

0.9
38
Price/Tangible Book 3.70
ONTY's Price/Tangible Book is ranked higher than
84% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 10.40 vs. ONTY: 3.70 )
ONTY' s 10-Year Price/Tangible Book Range
Min: 0.84   Max: 81
Current: 3.7

0.84
81
Earnings Yield (Greenblatt) -28.10
ONTY's Earnings Yield (Greenblatt) is ranked lower than
59% of the 1445 Companies
in the Global Biotechnology industry.

( Industry Median: -5.60 vs. ONTY: -28.10 )
ONTY' s 10-Year Earnings Yield (Greenblatt) Range
Min: -29.4   Max: 487.4
Current: -28.1

-29.4
487.4

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:3O6.Germany,
Oncothyreon Inc was incorporated on September 7, 2007. The Company is a clinical-stage biopharmaceutical company that develops therapeutic products for the treatment of cancer. Its cancer vaccines are designed to stimulate the immune system to attack cancer cells, while its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins. The Company's cancer vaccine product candidate, tecemotide, formerly known as L-BLP25 or Stimuvax, is being evaluated for the treatment of non-small cell lung cancer, or NSCLC. It has granted license to Merck KGaA of Darmstadt, Germany, or Merck KGaA, for the development, manufacture and commercialization of tecemotide. The Company is also conducting Phase 1 trial for ONT-10, a cancer vaccine. The Company's pipeline of products includes immunotherapies and small molecules. The Company currently outsources the manufacturing of drug substances and drug products for all of its products in clinical development. As of December 31, 2013 the Company owned approximately 25 U.S. patents and patent applications. It competes with pharmaceutical companies, biotechnology companies, public and private universities, government agencies and research organizations which are developing various approaches to cancer therapy. In addition to regulations in the United States, the Company will be subject to a variety of foreign regulations governing clinical trials and commercial sales and distribution of its product candidates.
» More Articles for ONTY

Headlines

Articles On GuruFocus.com
Value Betting with Special Situations: Lessons from the World of Gambling Mar 05 2013 
pro-longs life Jul 30 2011 
Cubist Pharmaceutical - Acutely Aware May 09 2010 
Cubist Pharmaceutical - Acutely Aware May 09 2010 
cooldecency99 note on ONTY May 01 2010 
creiter note on ONTY Jan 03 2010 

More From Other Websites
Biotech Stock Mailbag: ASCO Preview, CAR-T stocks, MannKind, Hate Mail! May 22 2015
ONCOTHYREON INC. Financials May 19 2015
Oncothyreon (ONTY) Looks Good: Stock Up 6.6% in Session - Tale of the Tape May 19 2015
Why Oncothyreon (ONTY) is Poised to Beat Earnings Estimates - Tale of the Tape May 19 2015
Will Oncothyreon (ONTY) Continue to Surge Higher? - Tale of the Tape May 18 2015
ONCOTHYREON INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Amendments to... May 14 2015
The 5 Winners and Losers From ASCO Presentations May 14 2015
10-Q for Oncothyreon, Inc. May 13 2015
Jumpstart ASCO '15 With This Quick List of Hot Research Abstracts May 13 2015
Oncothyreon reports 1Q loss May 11 2015
Oncothyreon reports 1Q loss May 11 2015
Oncothyreon Reports First Quarter 2015 Financial Results May 11 2015
Oncothyreon Inc Earnings Call scheduled for 4:30 pm ET today May 11 2015
ONCOTHYREON INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... May 11 2015
Oncothyreon Reports First Quarter 2015 Financial Results May 11 2015
10-K for Oncothyreon, Inc. May 07 2015
Oncothyreon Announces First Quarter 2015 Financial Results Conference Call May 04 2015
Oncothyreon Announces First Quarter 2015 Financial Results Conference Call May 04 2015
ONCOTHYREON INC. Files SEC form 8-K, Other Events Apr 21 2015
Oncothyreon (ONTY) Shares March Higher, Can It Continue? - Tale of the Tape Mar 18 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK